Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 5/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 5/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.36 |
| ▸ | KMO | O15229 | 2/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | APEX1 | P27695 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18285301 | 0.91 | P2RY14 (0.37) | ANO1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18285340 | 0.90 | KMO (0.36) | PDE4APDE4BPDE4CPDE4DKMO | |
| SCHEMBL18285312 | 0.90 | WDR5 (0.38) | PDE4APDE4BPDE4CPDE4DP2RY14 | |
| SCHEMBL18285360 | 0.87 | P2RY14 (0.40) | ANO1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18285299 | 0.87 | CNR1 (0.43) | ANO1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18706194 | 0.85 | P2RY14 (0.37) | ANO1PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL18286354 | 0.84 | P2RX3 (0.40) | PDE4APDE4BPDE4CPDE4DP2RY14 | |
| SCHEMBL18285306 | 0.83 | P2RY14 (0.51) | PDE4APDE4BPDE4CPDE4DP2RY14 | |
| SCHEMBL18293056 | 0.80 | GRM5 (0.35) | PDE4APDE4BPDE4CPDE4DP2RY14 | |
| SCHEMBL18285365 | 0.80 | P2RY14 (0.39) | PDE4APDE4BPDE4CPDE4DP2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3303299-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-24 | — | — | EP | claimed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | claimed |
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3303299-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | DRD3, GABRR3, DRD4 | ANO1 1134/4885PDE4A 2694/4885PDE4B 3171/4885 |
| US-10029989-B2 | Imidazole derivatives | DRD3, GABRR3, DRD4 | ANO1 1134/4885PDE4A 2694/4885PDE4B 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.